Overview of Parametric Survival Analysis for Health-Economic Applications

Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation

(2014) J Thompson Coon et al.   HEALTH TECHNOLOGY ASSESSMENT

Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves

(2012) Patricia Guyot et al.   BMC Medical Research Methodology

Modelling survival in hepatocellular carcinoma

(2012) Noemi Muszbek et al.   CURRENT MEDICAL RESEARCH AND OPINION

Improved curve fits to summary survival data: application to economic evaluation of health technologies

(2011) Martin W Hoyle et al.   BMC Medical Research Methodology

Treatment of follicular non-Hodgkin's lymphoma with or without rituximab: cost-effectiveness and value of information based on a 5-year follow-up

(2010) E. J. O. Soini et al.   ANNALS OF ONCOLOGY

Survival Models in Health Economic Evaluations: Balancing Fit and Parsimony to Improve Prediction

(2010) Christopher H Jackson et al.  

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial

(2010) Jack Cuzick et al.   LANCET ONCOLOGY

Accounting for uncertainty in health economic decision models by using model averaging

(2009) Christopher H. Jackson et al.   JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-STATISTICS IN SOCIETY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE